Jazz Pharmaceuticals
By therapeutic area
Not enough TA-specific data (need ≥3 deals per TA).
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 15 disclosed transactions, Jazz Pharmaceuticals concentrates its licensing activity in Neurology, Oncology, and Other. Jazz Pharmaceuticals pays a 1.33x premium over market median. Their most common deal structure is License, with an average disclosed value of $1.9B. Most recent activity: 2026.
Pipeline coverage & gaps
Jazz Pharmaceuticals has disclosed activity in 0 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 7 | $40M | $961M |
| Acquisition | 6 | $2.2B | $2.3B |
| Collaboration | 2 | — | $4.0B |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | oral KCNT1 inhibitor | Actio Biosciences | rare genetic epilepsies | preclinical | $820M | $1.3B |
| 2026 | ABS-1230 (KCNT1 inhibitor) | Actio Biosciences | epilepsy | unknown | $820M | $1.3B |
| 2026 | T cell engagers program | AbCellera Biologics | — | unknown | — | $4.0B |
| 2026 | T cell engager discovery and development program | AbCellera | oncology / immunology | discovery | — | $4.0B |
| 2025 | SAN2355 | Saniona | Epilepsy | preclinical | $43M | $1.0B |
| 2025 | dordaviprone | Chimerix | H3 K27M-mutant glioma (rare brain tumors) | phase_3 | $935M | $935M |
| 2025 | Diffuse glioma candidate | Chimerix | diffuse glioma / glioblastoma | unknown | — | $925M |
| 2024 | KRAS inhibitor programme | Redx Pharma | KRAS-mutant tumors | preclinical | $10M | $880M |
| 2022 | Zanidatamab | Zymeworks | Gastric, Biliary tract, Colorectal | phase_3 | $1.4B | $2.0B |
| 2022 | zanidatamab | Zymeworks Inc. | HER2-positive gastroesophageal adenocarcinoma | phase_2 | $50M | $1.8B |
| 2022 | DSP-0187 | Sumitomo Pharma | sleep-wake disorders | phase_1 | $50M | $1.1B |
| 2022 | JZP441 | Sumitomo Pharma Co., Ltd. | sleep disorders | phase_1 | $50M | $1.1B |
| 2020 | PF-04457845 | SpringWorks Therapeutics | — | unknown | $35M | $410M |
| 2020 | RXC006 | Redx Pharma | idiopathic pulmonary fibrosis (IPF) | preclinical | — | $360M |
| 2020 | epilepsy | GW Pharmaceuticals | epilepsy | approved | $7.2B | $7.2B |
How this is computed
For each Jazz Pharmaceuticals deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 4 disclosed deal premiums vs. peer medians. Raw premium 1.331, clamped to [0.7, 1.5].